These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21792861)

  • 1. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
    Trivers KF; Baldwin LM; Miller JW; Matthews B; Andrilla CH; Lishner DM; Goff BA
    Cancer; 2011 Dec; 117(23):5334-43. PubMed ID: 21792861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early adoption of BRCA1/2 testing: who and why.
    Armstrong K; Weiner J; Weber B; Asch DA
    Genet Med; 2003; 5(2):92-8. PubMed ID: 12644778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass.
    Goff BA; Miller JW; Matthews B; Trivers KF; Andrilla CH; Lishner DM; Baldwin LM
    Obstet Gynecol; 2011 Oct; 118(4):854-62. PubMed ID: 21934449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dental screening and referral of young children by pediatric primary care providers.
    dela Cruz GG; Rozier RG; Slade G
    Pediatrics; 2004 Nov; 114(5):e642-52. PubMed ID: 15520094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.
    Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C
    Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
    Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
    Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in BRCA testing: when insurance coverage is not a barrier.
    Olaya W; Esquivel P; Wong JH; Morgan JW; Freeberg A; Roy-Chowdhury S; Lum SS
    Am J Surg; 2009 Oct; 198(4):562-5. PubMed ID: 19800469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing.
    Van Riel E; Wárlám-Rodenhuis CC; Verhoef S; Rutgers EJ; Ausems MG
    Eur J Cancer Care (Engl); 2010 May; 19(3):369-76. PubMed ID: 19659662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
    Bellcross CA; Kolor K; Goddard KA; Coates RJ; Reyes M; Khoury MJ
    Am J Prev Med; 2011 Jan; 40(1):61-6. PubMed ID: 21146769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician use of genetic testing for cancer susceptibility: results of a national survey.
    Wideroff L; Freedman AN; Olson L; Klabunde CN; Davis W; Srinath KP; Croyle RT; Ballard-Barbash R
    Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):295-303. PubMed ID: 12692103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?
    Baldwin LM; Trivers KF; Matthews B; Andrilla CH; Miller JW; Berry DL; Lishner DM; Goff BA
    Ann Intern Med; 2012 Feb; 156(3):182-94. PubMed ID: 22312138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.